TNFRSF17 and myeloid sarcoma: A recent publication by Qin et al. in Cell reported on the first-in-human application of anti-BCMA chimeric antigen receptor (CAR)-T cell therapy in patients with treatment-refractory progressive multiple sclerosis (MS) with a good tolerability and efficacy.1